Literature DB >> 8988723

What constitutes long-term survival after surgery for hilar cholangiocarcinoma?

J Klempnauer1, G J Ridder, M Werner, A Weimann, R Pichlmayr.   

Abstract

BACKGROUND: Hilar cholangiocarcinomas are rarely considered to be resectable and specific data regarding long-term survival are not available.
METHODS: A retrospective single center experience from 1971 and 1995 details long-term survival among 339 patients who underwent surgery for adenocarcinoma of the hepatic duct bifurcation. Tumor removal was accomplished by resection of the bile duct bifurcation either alone (33 patients), in combination with hepatic resection (77 patients), or combined with hepatic and vascular resection (41 patients). Thirty-two patients underwent total hepatectomy and liver transplantation. In 188 patients the tumor was unresectable and palliative internal or external biliary drainage was established. The resectability rate was 49.2% and rose to 54% after inclusion of liver transplantation. The clinicopathologic features of 32 5-year survivors were compared with patients whose survival was less than 5 years.
RESULTS: Thirty-two patients survived longer than 5 years after surgical treatment of hilar cholangiocarcinoma; 22 of these patients (69%) were still alive at last follow-up. Twenty-six long-term survivors had primarily undergone resection; 4 received liver transplants. There was 1 long-term survivor beyond 5 years after both exploratory laparotomy and subsequent percutaneous transhepatic drainage, and palliative hepatojejunostomy. Long-term survival after resection was significantly associated with less advanced tumor stages. Lymph node involvement and residual tumor were the primary prognostic factors both in a multivariate analysis after resection and in the cohort of long-term survivors. Nevertheless, long-term survivors were still at a significant risk to die from tumor recurrence.
CONCLUSIONS: Radical resection offers the best possibility of prolonged survival with a good quality of life for patients with hilar cholangiocarcinoma.

Entities:  

Mesh:

Year:  1997        PMID: 8988723

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  49 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

Review 2.  Biliary tract surgery.

Authors:  S A Ahrendt
Journal:  Curr Gastroenterol Rep       Date:  1999-04

3.  Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection.

Authors:  Helmut Witzigmann; Frieder Berr; Ulrike Ringel; Karel Caca; Dirk Uhlmann; Konrad Schoppmeyer; Andrea Tannapfel; Christian Wittekind; Joachim Mossner; Johann Hauss; Marcus Wiedmann
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

4.  Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome.

Authors:  S D Mansfield; O Barakat; R M Charnley; B C Jaques; C B O'Suilleabhain; P J Atherton; D Manas
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

5.  Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma.

Authors:  Ryoko Sasaki; Yuichiro Takeda; Osamu Funato; Hiroyuki Nitta; Hidenobu Kawamura; Noriyuki Uesugi; Tamotsu Sugai; Go Wakabayashi; Nobuhiro Ohkohchi
Journal:  World J Surg       Date:  2007-07-25       Impact factor: 3.352

6.  Liver transplantation is not indicated for cholangiocarcinoma.

Authors:  C Wright Pinson; Derek E Moore
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

7.  Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis.

Authors:  Caitlin Hester; Ibrahim Nassour; Beverley Adams-Huet; Mathew Augustine; Michael A Choti; Rebecca M Minter; John C Mansour; Patricio M Polanco; Matthew R Porembka; Sam C Wang; Adam C Yopp
Journal:  J Gastrointest Surg       Date:  2018-07-20       Impact factor: 3.452

8.  Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies.

Authors:  Yoshifumi Kawarada; Bidhan C Das; Tatsushi Naganuma; Masami Tabata; Hiroki Taoka
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

9.  Cholangiocarcinoma: a 7-year experience at a single center in Greece.

Authors:  Alexandra Alexopoulou; Aspasia Soultati; Spyros-P Dourakis; Larissa Vasilieva; Athanasios-J Archimandritis
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

10.  [Is there a nonsurgical therapeutic approach to cholangiocellular carcinomas?].

Authors:  M Fuchs; W Schepp
Journal:  Chirurg       Date:  2006-04       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.